Zibotentan placebo
Sponsors
Astrazeneca AB
Conditions
Cirrhosis of the liver is a condition in which the liver is scarred and damagedLiver cirrhosis with features of portal hypertension.
Phase 2
A Two Part Phase IIa/b Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Dose ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension
CompletedCTIS2023-505405-17-00
Start: 2022-10-07End: 2025-07-17Target: 111Updated: 2025-02-07
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy as well as Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants with Cirrhosis
CompletedCTIS2023-506893-11-00
Start: 2024-04-19End: 2024-12-09Target: 36Updated: 2024-12-11